Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announce
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimat
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and

Twist Bioscience: A Post-Earnings Assessment

03:16pm, Monday, 18'th Nov 2024
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for seve
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Found
Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation m
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point inc

The 3 Best Med Tech Stocks to Buy Now

11:20am, Monday, 05'th Aug 2024
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and heal
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. T
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE